Easterly Investment Partners LLC lowered its position in shares of OptiNose, Inc. (NASDAQ:OPTN - Free Report) by 98.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 46,667 shares of the company's stock after selling 2,312,572 shares during the quarter. Easterly Investment Partners LLC owned 0.46% of OptiNose worth $312,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. State Street Corp grew its holdings in shares of OptiNose by 14.2% in the 3rd quarter. State Street Corp now owns 341,303 shares of the company's stock worth $229,000 after acquiring an additional 42,500 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of OptiNose by 33.7% in the third quarter. Geode Capital Management LLC now owns 1,298,333 shares of the company's stock valued at $870,000 after purchasing an additional 326,918 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in OptiNose by 5.3% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,075,638 shares of the company's stock worth $2,061,000 after acquiring an additional 155,329 shares during the period. Finally, FMR LLC boosted its holdings in shares of OptiNose by 3.2% during the third quarter. FMR LLC now owns 16,541,849 shares of the company's stock worth $11,083,000 after purchasing an additional 518,610 shares during the period. 85.60% of the stock is owned by institutional investors and hedge funds.
Insider Activity at OptiNose
In other news, CEO Ramy A. Mahmoud sold 6,376 shares of OptiNose stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $5.29, for a total value of $33,729.04. Following the sale, the chief executive officer now directly owns 126,931 shares in the company, valued at $671,464.99. This trade represents a 4.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders have sold 8,213 shares of company stock valued at $43,643. 2.30% of the stock is owned by corporate insiders.
OptiNose Price Performance
OptiNose stock remained flat at $9.15 during midday trading on Monday. 80,146 shares of the company traded hands, compared to its average volume of 63,122. OptiNose, Inc. has a twelve month low of $4.82 and a twelve month high of $22.35. The stock has a market capitalization of $92.05 million, a PE ratio of -2.18 and a beta of -0.30. The firm has a 50 day moving average price of $6.30 and a two-hundred day moving average price of $7.90.
OptiNose (NASDAQ:OPTN - Get Free Report) last released its quarterly earnings data on Wednesday, March 26th. The company reported ($0.03) EPS for the quarter, beating analysts' consensus estimates of ($0.70) by $0.67. The firm had revenue of $21.47 million during the quarter, compared to the consensus estimate of $21.02 million. On average, research analysts forecast that OptiNose, Inc. will post -3.22 EPS for the current fiscal year.
Analysts Set New Price Targets
OPTN has been the subject of several recent research reports. Lake Street Capital cut OptiNose from a "buy" rating to a "hold" rating and lowered their price target for the company from $17.00 to $9.00 in a research note on Thursday, March 20th. Piper Sandler restated a "neutral" rating and set a $9.00 price objective (down from $15.00) on shares of OptiNose in a research report on Friday, March 21st. Finally, HC Wainwright restated a "neutral" rating and set a $9.00 target price (down previously from $18.00) on shares of OptiNose in a research report on Friday, March 21st.
Get Our Latest Research Report on OptiNose
About OptiNose
(
Free Report)
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.
Further Reading
Before you consider OptiNose, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OptiNose wasn't on the list.
While OptiNose currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
